SELLAS Life Sciences updates cash and shares
SELLAS Life Sciences Group, Inc. provides an update on its cash position and share count.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
SELLAS Life Sciences Group, Inc. provides an update on its cash position and share count. The company had $107.1 million in cash and cash equivalents as of March 31, 2026. In April and May 2026, it received about $28.7 million from the exercise of common stock warrants, adding to its liquidity.
As of June 2, 2026, SELLAS had 196,632,574 shares of common stock outstanding, giving investors a clearer picture of the current capital structure.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Cash and cash equivalents: $107.1 million
Warrant exercise proceeds: $28.7 million
Shares outstanding: 196,632,574 shares
+1 more
4 metrics
Cash and cash equivalents
$107.1 million
As of March 31, 2026
Warrant exercise proceeds
$28.7 million
Proceeds received in April and May 2026
Shares outstanding
196,632,574 shares
Common stock outstanding as of June 2, 2026
Trading market
The Nasdaq Stock Market LLC
Listing venue for SLS common stock
Key Terms
Emerging growth company, common stock warrants, cash and cash equivalents, Common Stock, $0.0001 par value per share, +1 more
5 terms
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
common stock warrants financial
"received approximately $28.7 million in proceeds from the exercise of common stock warrants"
Common stock warrants are tradable certificates that give the holder the right, but not the obligation, to buy a company’s common shares at a fixed price before a specified expiration date. They work like long-term options issued by the company and can provide cheaper, leveraged exposure to a stock’s potential upside; however, if holders use the warrants to buy shares, the total number of shares increases, which can dilute the value of existing shares.
cash and cash equivalents financial
"had $107.1 million of cash and cash equivalents"
Cash and cash equivalents are the money a company has on hand plus very short-term, low-risk investments that can be quickly turned into cash, like bank deposits or government bills. Investors watch this figure because it shows a company’s immediate ability to pay bills, cover unexpected costs, and fund operations or growth — like a household’s checking account and emergency fund that keeps daily life running smoothly.
Form 8-K regulatory
"Check the appropriate box below if the Form 8-K filing is intended"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What cash balance did SELLAS Life Sciences (SLS) report as of March 31, 2026?
SELLAS Life Sciences reported cash and cash equivalents of $107.1 million as of March 31, 2026. This figure represents the company’s available cash resources at quarter-end before later warrant exercise proceeds added further liquidity.
How much cash did SELLAS Life Sciences (SLS) receive from warrant exercises in April and May 2026?
SELLAS Life Sciences received approximately $28.7 million in proceeds from the exercise of common stock warrants in April and May 2026. These proceeds increased the company’s cash resources following the March 31, 2026 balance of $107.1 million.
What type of financial update did SELLAS Life Sciences (SLS) provide in this 8-K?
SELLAS Life Sciences provided a brief financial update on cash, warrant proceeds, and shares outstanding. It disclosed cash of $107.1 million as of March 31, 2026, additional warrant proceeds of $28.7 million, and 196,632,574 shares outstanding as of June 2, 2026.
Does the SELLAS Life Sciences (SLS) update mention its stock exchange listing?
Yes. The update notes that SELLAS Life Sciences’ common stock, with a par value of $0.0001 per share, trades under the symbol SLS on The Nasdaq Stock Market LLC, confirming its continued listing on this exchange.
AI-generated analysis. How Rhea-AI works. Not financial advice.
